| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8775281 | Urology | 2018 | 29 Pages |
Abstract
Yearly PSA screening is highly effective in reducing both prostate cancer mortality and all-cause mortality in men with prostate cancer, and when combined with active surveillance to prevent overtreatment, lends support for PSA screening for men in good health aged 55-75.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Paul F. Alpert,